A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

NCT05830097 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer, Breast
Cancer, Lung
Cancer of Pancreas
Cancer of Esophagus
Cancer Colorectal

Interventions

DRUG: CBP-1019

Sponsor

Coherent Biopharma (Hefei) Co., Ltd.